Clinical Trials Sponsored by Richard H. Lee

Total 553 results

H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Terminated

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

Liver Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma Stage IV | BRAF V600 Mutation | Melanoma Stage III

United States
H. Lee Moffitt Cancer Center and Research Institute
Amgen

Active, not recruiting

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Breast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Exelixis

Completed

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Bladder Cancer | Carcinoma in Situ of Bladder

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Cancer of the Bile Duct

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Cholangiocarcinoma | Gastrointestinal Tumor | Gall Bladder Carcinoma | Biliary Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

Pancreatic Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
GlaxoSmithKline

Completed

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

Cancer Cachexia

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem

Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

Rectal Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Yoga for Aromatase Inhibitor-associated Joint Pain

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Facts and Attitudes About Clinical Trials (FACT)

Cancer | Neoplasm

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Neuroendocrine Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Completed

Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC

Non-Small Cell Lung Cancer

United States, Germany, Puerto Rico
H. Lee Moffitt Cancer Center and Research Institute
GlaxoSmithKline

Completed

A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

Rectal Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

Sarcoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

Tobacco Dependence

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Terminated

Depocyt® With Sorafenib in Neoplastic Meningitis

Neoplastic Meningitis

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

Glioblastoma | Anaplastic Astrocytoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Neuroendocrine Tumor | Islet Cell Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Completed

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Gastric Cancer | Esophageal Cancer

United States, Puerto Rico
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Terminated

A Phase I/II Study of Sunitinib and Dacarbazine

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Vaccinex Inc.

Recruiting

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

HER2-positive Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Recruiting

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Myelodysplastic Syndromes

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Active, not recruiting

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals

Active, not recruiting

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Hormone Receptor-positive Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
ModernaTX, Inc.

Completed

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

Covid19 | SARS-CoV2 Infection

United States
H. Lee Moffitt Cancer Center and Research Institute
Array BioPharma

Completed

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Non-Small Cell Lung Cancer | Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals

Terminated

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Cutaneous Squamous Cell Carcinoma of the Head and Neck | Cutaneous Squamous Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Completed

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

Myelomonocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Olympus Corporation

Completed

Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas

Glioma | Brain Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
Aprea Therapeutics

Completed

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm

United States
Eleos, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Terminated

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

Chronic Phase Chronic Myeloid Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Completed

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis; Amgen

Withdrawn

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Seagen Inc.

Terminated

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Peripheral T-Cell Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

Mantle Cell Lymphoma | Lymphocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Angiodynamics, Inc.

Recruiting

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Locally Advanced Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Gilead Sciences

Not yet recruiting

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Breast Cancer | Triple Negative Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Recruiting

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Diffuse Large B Cell Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Adaptive Biotechnologies

Recruiting

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Boehringer Ingelheim

Recruiting

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Squamous Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Recruiting

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

HER2-positive Breast Cancer | Leptomeningeal Disease | Leptomeningeal Metastasis

United States

Clinical Trials Sponsored by Richard H. Lee

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations